Guidant: The Gift That Keeps on Giving

By Brian Orelli | More Articles
November 9, 2009 | Comments (2)

Watch stocks you care about

The single, easiest way to keep track of all the stocks that matter...

Your own personalized stock watchlist!

It's a 100% FREE Motley Fool service...

Click Here Now

Boston Scientific (NYSE: BSX ) hasn't had a fiscal year of positive GAAP earnings since it bought Guidant in April 2006. It looks like it'll finally have one this year, but owning Guidant will now cost the company nearly all of what has been earned so far this year -- nearly half of the full year's projected earnings.

Last year, Boston Scientific took a whopping $2.7 billion goodwill writedown because it had to downgrade the value of what it got in acquiring Guidant. Now it's taking a measly $296 million charge to settle a dispute with the Department of Justice for failing to include information about three of Guidant's heart devices in reports to the Food and Drug Administration. The company also pleaded guilty to two misdemeanors in connection with the case.

However, the reports to the FDA happened the year before Boston Scientific bought Guidant. And the company already paid $240 million to settle lawsuits filed by patients claiming that Guidant knew about defects in its defibrillators. Johnson & Johnson (NYSE: JNJ ) , which bowed out of a bidding war over Guidant, is looking pretty smart right now.

The nearly $300 million fine could have been worse, I guess. Pfizer (NYSE: PFE ) and Eli Lilly (NYSE: LLY ) each settled cases with the DOJ for at least $1.4 billion in the past year.

Even though the Guidant acquisition has been plagued by more than its share of heart-wrenching issues, investors may have more joy in their hearts than heartache in their future. The heart-rhythm devices acquired from Guidant should get a boost from a recent study, and its Promus drug-eluting stent is doing well. That stent is made by Abbott Labs (NYSE: ABT ) as part of the deal that split Guidant between the two companies, and is identical -- except for the packaging -- to Abbott's Xience V. Boston Scientific doesn't take in as much profit from the stent as its wholly owned older stent, but at least its revenue is holding steady among increased competition.

With any luck, it's done sending that revenue out the one-time-charges door.

Best Odds in the Universe!
If you're interested in a 98.79% chance at beating the market... and a 70.84% chance at DOUBLING the market's return – Motley Fool Supernova could be just what you're looking for. And get this: We arrived at these odds from 10,000 random back-tested portfolios composed of Motley Fool Co-founder David Gardner's personal stock picks.

It's why David recently handpicked a small team of world-class portfolio managers. You see, he thinks these odds can get even better! And he'd like to prove it to you...

Simply enter your email address. And the answer to the question everybody is asking will be delivered to your inbox!

Pfizer is a Motley Fool Inside Value selection. Johnson & Johnson is an Income Investor recommendation. Try any of our Foolish newsletters today, free for 30 days.

Fool contributor Brian Orelli, Ph.D., doesn't own shares of any company mentioned in this article. The Fool has a disclosure policy.

Read/Post Comments (2) | Recommend This Article (2)

Comments from our Foolish Readers

Help us keep this a respectfully Foolish area! This is a place for our readers to discuss, debate, and learn more about the Foolish investing topic you read about above. Help us keep it clean and safe. If you believe a comment is abusive or otherwise violates our Fool's Rules, please report it via the Report this Comment icon found on every comment.

Report this Comment On November 09, 2009, at 8:15 PM, mktwiz2009 wrote:

Gee Brian Orelli, interesting article...Just curious if you know how much of the $2.7B write down was funded by revenue that was produced by former Guidant businesses that were acquired by BSX? In other words, did they pay for themselves? Also, without Guidant's businesses, specifically CRM, where would BSX be today in a hyper-competitive interventional cardiology (stent) market? Your lack of analysis is disappointing.
Report this Comment On November 10, 2009, at 1:31 AM, TMFBiologyFool wrote:

I don't think the extrinsic Guidant profits have paid for the purchase yet (at least on a GAAP basis). That's the point of the opening sentence.
But you're right, Boston Scientific would be in a bad place had it not diversified and that was the point of my second-to-last paragraph. The future doesn't look nearly as bad as the past.

Add your comment.

Compare Brokers

Fool Disclosure

DocumentId: 1038454, ~/Articles/ArticleHandler.aspx, 2/15/2012 12:58:57 AM

Report This Comment

Use this area to report a comment that you believe is in violation of the community guidelines. Our team will review the entry and take any appropriate action.

Sending report...

Today's Market

updated 2 hours ago Sponsored by:
	DOW	12,878.28	4.24	0.03%
	S&P 500	1,350.50	-1.27	-0.09%
	NASD	2,931.83	0.44	0.02%

Create My Watchlist

Go to My Watchlist

You don't seem to be following any stocks yet!

Better investing starts with a watchlist. Now you can create a personalized watchlist and get immediate access to the personalized information you need to make successful investing decisions.

Data delayed up to 5 minutes